Nivolumab biosimilar - Mabpharm
Alternative Names: CMAB 819Latest Information Update: 19 Apr 2024
At a glance
- Originator Sinomab
- Developer Mabpharm
- Class Antineoplastics; Antivirals; Immunotherapies; Monoclonal antibodies
- Mechanism of Action Antibody-dependent cell cytotoxicity; Programmed cell death 1 receptor antagonists; T lymphocyte stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase I Liver cancer; Non-small cell lung cancer; Squamous cell cancer
Most Recent Events
- 19 Apr 2024 Phase I development for Liver cancer, Non-small cell lung cancer (Metastatic disease) and Squamous cell cancer (Locally recurrent, Metastatic disease, Second-line therapy or greater) is ongoing in China (Taizhou Mabtech Pharmaceutical pipeline, April 2024)
- 16 Oct 2023 Taizhou Mabtech Pharmaceutical terminates a phase I trial in Squamous cell cancer (Metastatic disease, Locally recurrent, Second-line therapy or greater) in China (IV) due to early positive results due to difficulty in recruiting subjects (NCT04659369)
- 24 Sep 2020 Phase-I clinical trials in Squamous cell cancer (Metastatic disease, Locally recurrent, Second-line therapy or greater) in China (IV) in September 2020 (NCT04659369)